{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:00:52Z","timestamp":1791234052731,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41391-023-00752-5","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T21:03:25Z","timestamp":1700514205000},"page":"645-653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1789-9687","authenticated-orcid":false,"given":"A.","family":"Saouli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Touzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Beauval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dergamoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ziouziou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Deffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ouzzane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"752_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11864-016-0439-8","volume":"17","author":"DJ Stevens","year":"2016","unstructured":"Stevens DJ, Sooriakumaran P. Oligometastatic prostate cancer. Curr Treat Options Oncol. 2016;17:62.","journal-title":"Curr Treat Options Oncol"},{"key":"752_CR2","doi-asserted-by":"publisher","first-page":"8491","DOI":"10.18632\/oncotarget.3455","volume":"6","author":"DK Reyes","year":"2015","unstructured":"Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6:8491\u2013524.","journal-title":"Oncotarget"},{"key":"752_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boev\u00e9","year":"2019","unstructured":"Boev\u00e9 LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75:410\u20138.","journal-title":"Eur Urol"},{"key":"752_CR4","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trials. Lancet. 2018;392:2353\u201366.","journal-title":"Lancet."},{"key":"752_CR5","doi-asserted-by":"crossref","unstructured":"Cornford P, van den Bergh RCN, Mottet N. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021;79:263\u201382.","DOI":"10.1016\/j.eururo.2020.09.046"},{"key":"752_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijrobp.2010.01.072","volume":"80","author":"A Solberg","year":"2011","unstructured":"Solberg A, Haugen OA, Viset T, Bergh A, Tasdemir I, Ahlgren G, et al. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80:55\u201361.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"752_CR7","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1200\/JCO.2010.33.2999","volume":"29","author":"V Tzelepi","year":"2011","unstructured":"Tzelepi V, Efstathiou E, Wen S, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011;29:2574\u201381.","journal-title":"J Clin Oncol"},{"key":"752_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.eururo.2017.08.016","volume":"73","author":"T Knoll","year":"2018","unstructured":"Knoll T, Omar MI, Maclennan S, et al. Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of urology. Eur Urol. 2018;73:290\u2013300.","journal-title":"Eur Urol"},{"key":"752_CR9","unstructured":"Moga C, Guo B, Schopflocher DP, Harstall C. Development of a quality appraisal tool for case series. Stud Using a Modif Delphi Tech (2012)."},{"key":"752_CR10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","volume":"193","author":"A Heidenreich","year":"2015","unstructured":"Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193:832\u20138.","journal-title":"J Urol"},{"key":"752_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.eururo.2016.08.040","volume":"72","author":"G Gandaglia","year":"2017","unstructured":"Gandaglia G, Fossati N, Stabile A, Bandini M, Rigatti P, Montorsi F, et al. Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up. Eur Urol. 2017;72:289\u201392.","journal-title":"Eur Urol"},{"key":"752_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.eururo.2015.05.023","volume":"69","author":"P Sooriakumaran","year":"2016","unstructured":"Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol. 2016;69:788\u201394.","journal-title":"Eur Urol"},{"key":"752_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.euf.2017.06.016","volume":"3","author":"T Steuber","year":"2017","unstructured":"Steuber T, Berg KD, R\u00f8der MA, Brasso K, Iversen P, Huland H, et al. Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study. Eur Urol Focus. 2017;3:646\u20139.","journal-title":"Eur Urol Focus"},{"key":"752_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.urology.2017.02.051","volume":"106","author":"F Poelaert","year":"2017","unstructured":"Poelaert F, Verbaeys C, Rappe B, Kimpe B, Billiet I, Plancke H, et al. Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective LoMP trial. Urology. 2017;106:146\u201352.","journal-title":"Urology"},{"key":"752_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.urology.2016.10.044","volume":"102","author":"MJ O\u2019Shaughnessy","year":"2017","unstructured":"O\u2019Shaughnessy MJ, McBride SM, Vargas HA, Touijer KA, Morris MJ, Danila DC, et al. A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer. Urology. 2017;102:164\u201372.","journal-title":"Urology"},{"key":"752_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/bju.13992","volume":"121","author":"WS Jang","year":"2018","unstructured":"Jang WS, Kim MS, Jeong WS, Chang KD, Cho KS, Ham WS, et al. Does robot-assisted radical prostatectomy benefit prostate cancer patients with bone oligometastases? BJU Int. 2018;121:225\u201331.","journal-title":"BJU Int"},{"key":"752_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.euo.2018.03.002","volume":"1","author":"A Heidenreich","year":"2018","unstructured":"Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, et al. Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases. Eur Urol Oncol. 2018;1:46\u201353.","journal-title":"Eur Urol Oncol"},{"key":"752_CR18","doi-asserted-by":"crossref","unstructured":"S Knipper, B Beyer, P Mandel, P Tennstedt, D Tilki, T Steuber et al. Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H. World J Urol. 2020;38:1459\u201364.","DOI":"10.1007\/s00345-019-02950-0"},{"key":"752_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.urology.2019.03.040","volume":"131","author":"T Lan","year":"2019","unstructured":"Lan T, Chen Y, Su QJ, Ye JJ. Oncological outcome of cytoreductive radical prostatectomy in prostate cancer patients with bone oligometastases. Urology. 2019;131:166\u201375.","journal-title":"Urology"},{"key":"752_CR20","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/pros.24170","volume":"81","author":"S Si","year":"2021","unstructured":"Si S, Zheng B, Wang Z, Niu Z. Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis. Prostate. 2021;81:736\u201344.","journal-title":"Prostate"},{"key":"752_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"SWR Hellman","year":"1995","unstructured":"Hellman SWR. Oligometastases. J Clin Oncol. 1995;13:8\u201310.","journal-title":"J Clin Oncol"},{"key":"752_CR22","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(18)30571-0","volume":"19","author":"FE Lecouvet","year":"2018","unstructured":"Lecouvet FE, Oprea-Lager DE, Liu Y, Ost P, Bidaut L, Collette L, et al. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncol. 2018;19:e534\u2013e545.","journal-title":"Lancet Oncol"},{"key":"752_CR23","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/ijc.24353","volume":"125","author":"D Wuttig","year":"2009","unstructured":"Wuttig D, Baier B, Fuessel S, et al. Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer. 2009;125:474\u201382.","journal-title":"Int J Cancer"},{"key":"752_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrurol.2016.175","volume":"14","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14:15\u201325.","journal-title":"Nat Rev Urol"},{"key":"752_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","volume":"11","author":"Y Liu","year":"2018","unstructured":"Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11:104.","journal-title":"J Hematol Oncol"},{"key":"752_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2009.07.049","volume":"57","author":"PA Abrahamsson","year":"2010","unstructured":"Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010;57:49\u201359.","journal-title":"Eur Urol"},{"key":"752_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467\u201379.","journal-title":"Eur Urol"},{"key":"752_CR28","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","volume":"65","author":"SH Culp","year":"2014","unstructured":"Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumour? A SEER-based study. Eur Urol. 2014;65:1058\u201366.","journal-title":"Eur Urol"},{"key":"752_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-014-0455-9","volume":"15","author":"C Gratzke","year":"2014","unstructured":"Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in clinically non-organ-confined prostate cancer. Curr Urol Rep. 2014;15:455.","journal-title":"Curr Urol Rep."},{"key":"752_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrclinonc.2011.64","volume":"8","author":"E Comen","year":"2011","unstructured":"Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011;8:369\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"752_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.eururo.2015.04.036","volume":"69","author":"CE Bayne","year":"2016","unstructured":"Bayne CE, Williams SB, Cooperberg MR, et al. Treatment of the primary tumor in metastatic prostate cancer: current concepts and future perspectives. Eur Urol. 2016;69:775\u201387.","journal-title":"Eur Urol"},{"key":"752_CR32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3349\/ymj.2018.59.5.567","volume":"59","author":"KC Koo","year":"2018","unstructured":"Koo KC, Dasgupta P. Treatment of oligometastatic hormone-sensitive prostate cancer: a comprehensive review. Yonsei Med J. 2018;59:567\u201379.","journal-title":"Yonsei Med J"},{"key":"752_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","volume":"77","author":"L Moris","year":"2020","unstructured":"Moris L, Cumberbatch MG, Van den Broeck T, Gandaglia G, Fossati N, Kelly B, et al. Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review. Eur Urol. 2020;77:614\u201327.","journal-title":"Eur Urol"},{"key":"752_CR34","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/S1166-7087(19)30167-8","volume":"29","author":"F Kleinclauss","year":"2019","unstructured":"Kleinclauss F, Thiery-Vuillemin A. Prise en charge du cancer de la prostate oligo-m\u00e9tastatique. Progr\u00e8s en urologie. 2019;29:S20\u2013S34.","journal-title":"Progr\u00e8s en urologie"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00752-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T13:03:55Z","timestamp":1730984635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00752-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1038\/s41391-023-00752-5","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"assertion":[{"value":"13 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}